Evolving Paradigms in the Use of Checkpoint Inhibitors for the Management of Patients With Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases with most patients having advanced disease at the time of diagnosis. Recent updates to guidelines have further defined recommendations for screening, diagnosis, and biomarker testing for the early management of NSCLC. However, the COVID-19 pandemic has complicated the diagnosis and management of NSCLC, potentially impacting clinical outcomes in these patients. Treatment paradigms also continue to rapidly expand for these patients, making optimal selection of individualized therapies challenging. Within this 6-part podcast series, experts in the field review current recommendations for the optimal management of patients with NSCLC in the shifting clinical setting of the COVID-19 pandemic, assess best practices for testing and interpretation of test results for management of patients with advanced NSCLC, as well as evaluate first-line treatment options for patients with advanced NSCLC lacking oncogenic driver aberrations, sequencing and combinations of immuno-oncology (IO) regimens for patients with NSCLC who have progressed on first-line treatment, and the use of checkpoint inhibitors for patients with NSCLC.